Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Next Previous
X
Search
Trial Profile

A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QR 313 (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms WINGS
  • Sponsors Phoenicis Therapeutics; ProQR Therapeutics; Wings Therapeutics

    • Most Recent Events

    • 19 Aug 2021 Status changed from recruiting to discontinued due to low enrollment.
    • 29 Jan 2021 This trial has been discontinued in France , according to European Clinical Trials Database record.
    • 03 Jun 2020 This trial has been discontinued in Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top